Latest Breaking News On - Ciron drugs pharmaceuticals - Page 1 : vimarsana.com
Share this article
Share this article
ResearchAndMarkets.com's offering.
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021-2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affecting around one-fourth of the global population, especially women and children. It is one of the predominant causes of anemia. Anemia accounts for around 9% of the total global disease burden. Several chronic diseases are frequently associated with iron deficiency anemia (IDA) such as chronic kidney disease (CKD), chronic heart failure, cancer, and inflammatory bowel diseases. As anemia is associated with chronic fatigue, diminished well-being, and impaired cognitive function, the treatment with oral and IV iron drugs reduces the need for blood transfusion in patients. Further, the WHO rates ID as the most common and widespread nutritional disorder globally, and its prevalence is expected to grow with the aging population and the incidence of various chronic disorders.
AustraliaJapanUnited-statesUnited-kingdomArgentinaBrazilChinaSouth-africaCanadaDublinIrelandGermanyShare this article
Share this article
ResearchAndMarkets.com's offering.
This report features an extensive study of the current market landscape and the future potential of sterile fill/finish services for small molecule drugs. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In fact, in 2019, the FDA's Center for Drug Evaluation and Research approved 48 small molecule drugs, representing 70% of the new molecular entities (NMEs) clearing regulatory review in the same year. Given that the demand for small molecule drugs is still on the rise, the importance of contract manufacturing and third party services is also increasing in the pharmaceutical industry. Sterile fill/finish is considered among the most crucial steps in the pharmaceutical production process. In fact, aseptic conditions during fill/finish operations are not only essential for ensuring end user safety, but also maintaining pharmacological efficacy and product quality. As small molecule APIs are gradually becoming more complex, the demand for appropriate aseptic fill/finish processes is growing.
GermanyBerkshireUnited-kingdom-generalUnited-kingdomAustraliaUnited-statesIndiaItalyCironCentreFranceCanada